Intercept to Present at the 2021 Cantor Virtual Global Healthcare Conference
September 21, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to...
Intercept Pharmaceuticals Announces Convertible Notes Repurchase
September 13, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on the development and commercialization of novel...
Intercept to Present at the Virtual Baird 2021 Global Healthcare Conference
September 01, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to...
Intercept Pharmaceuticals Announces Convertible Notes Exchange, New Issuance and Stock Repurchase
August 10, 2021 21:43 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on the development and commercialization of novel...
Intercept Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
July 29, 2021 07:00 ET
|
Intercept Pharmaceuticals, Inc.
Worldwide Ocaliva® net sales of $96.6 million, representing 25% growth over the prior year quarter Company reiterates 2021 financial guidance of Ocaliva net sales guidance of $325 million to...
Intercept to Announce Second Quarter 2021 Financial Results on July 29, 2021
July 19, 2021 07:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, July 19, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
Intercept to Present New NASH and PBC Data at the Digital International Liver Congress™ 2021
June 21, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
New analyses from the Phase 3 REGENERATE study highlight the relationship between early reductions of aminotransferases and fibrosis improvement in patients with fibrosis due to NASH treated with...
Intercept to Present at the Raymond James 2021 Human Health Innovation Conference
June 15, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
Intercept Appoints M. Michelle Berrey, M.D., M.P.H., as President of Research & Development and Chief Medical Officer
June 09, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
Intercept Appoints Andrew Saik as Chief Financial Officer
June 07, 2021 08:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, June 07, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat...